Patents by Inventor Mark W. Surber

Mark W. Surber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF
    Publication number: 20220047604
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Application
    Filed: March 26, 2021
    Publication date: February 17, 2022
    Inventors: Mark W. SURBER, Keith A. BOSTIAN, Michael N. DUDLEY, Olga RODNY, David C. GRIFFITH
  • AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS
    Publication number: 20210121472
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Application
    Filed: June 16, 2020
    Publication date: April 29, 2021
    Inventors: David C. GRIFFITH, Michael N. DUDLEY, Mark W. SURBER, Keith A. BOSTIAN, Olga RODNY
  • Aerosolized fluoroquinolones and uses thereof
    Patent number: 10987357
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: April 27, 2021
    Assignee: Horizon Orphan, LLC
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 10722519
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 28, 2020
    Assignee: Horizon Orphan LLC
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF
    Publication number: 20190381057
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Application
    Filed: January 17, 2019
    Publication date: December 19, 2019
    Inventors: Mark W. SURBER, Keith A. BOSTIAN, Michael N. DUDLEY, Olga RODNY, David C. GRIFFITH
  • AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS
    Publication number: 20190321371
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Application
    Filed: November 19, 2018
    Publication date: October 24, 2019
    Inventors: David C. GRIFFITH, Michael N. DUDLEY, Mark W. SURBER, Keith A. BOSTIAN, Olga RODNY
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 10149854
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: December 11, 2018
    Assignee: Horizon Orphan LLC
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS
    Publication number: 20180104252
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Application
    Filed: June 28, 2017
    Publication date: April 19, 2018
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 9717738
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 1, 2017
    Assignee: Horizon Orphan LLC
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS
    Publication number: 20160287606
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Application
    Filed: April 18, 2016
    Publication date: October 6, 2016
    Applicant: Raptor Pharmaceuticals Inc.
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF
    Publication number: 20160279138
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: Raptor Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 9326936
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: May 3, 2016
    Assignee: Raptor Pharmaceuticals, Inc.
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS
    Publication number: 20140329810
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: David C. GRIFFITH, Michael N. DUDLEY, Mark W. SURBER, Keith A. BOSTIAN, Olga RODNY
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 8815838
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: August 26, 2014
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF
    Publication number: 20140066441
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Application
    Filed: August 28, 2013
    Publication date: March 6, 2014
    Applicant: MPEX PHARMACEUTICALS, INC.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny (Lomovskaya), David C. Griffith
  • Aerosolized fluoroquinolones and uses thereof
    Patent number: 8546423
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: October 1, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Aerosolized fluoroquinolones and uses thereof
    Patent number: 8524734
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: September 3, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Aerosolized fluoroquinolones and uses thereof
    Patent number: 8524735
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: September 3, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Immunogenic minicells and methods of use
    Patent number: 8524484
    Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: September 3, 2013
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber, Matthew J. Giacalone
  • Aerosolized fluoroquinolones and uses thereof
    Patent number: 8357696
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: January 22, 2013
    Assignee: Mpex Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith